The Manufacturers Life Insurance Company Has $196,000 Stock Holdings in Urogen Pharma $URGN

The Manufacturers Life Insurance Company decreased its position in shares of Urogen Pharma (NASDAQ:URGN) by 80.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 10,909 shares of the company’s stock after selling 44,777 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Urogen Pharma were worth $196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Paradigm Biocapital Advisors LP boosted its position in shares of Urogen Pharma by 6.1% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock valued at $104,773,000 after acquiring an additional 257,564 shares during the period. Morgan Stanley increased its position in Urogen Pharma by 1.4% during the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock worth $60,023,000 after acquiring an additional 34,455 shares during the period. Soleus Capital Management L.P. acquired a new stake in Urogen Pharma in the 2nd quarter worth about $29,934,000. SG Americas Securities LLC raised its stake in Urogen Pharma by 20.3% in the 1st quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after purchasing an additional 280,199 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Urogen Pharma in the 4th quarter valued at about $26,350,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN opened at $49.14 on Tuesday. Urogen Pharma has a one year low of $15.86 and a one year high of $49.67. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -24.82 and a beta of 1.57. The firm has a 50 day simple moving average of $38.96 and a 200 day simple moving average of $28.36.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. As a group, analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on URGN. UBS Group restated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price target on shares of Urogen Pharma in a research report on Wednesday, July 15th. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 price target for the company. Oppenheimer raised their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Finally, Guggenheim lifted their price objective on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.38.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. The trade was a 7.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 25,222 shares of company stock worth $892,661. Company insiders own 4.80% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.